Works matching IS 3005074X AND DT 2024 AND VI 8 AND IP 1

Results: 8

Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry.

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00226-4

By:

Tually, Pete;
Quinto, Virginia García;
Omar, Yehia;
Novruzov, Fuad;
Yudistiro, Ryan;
Sathekge, Mike;
Currie, Geoffrey;
Galette, Paul;
Patel, Neel;
Brown, Tracey;
Bolland, Gabriel;
Lo Bue, Rebecca;
Cade, David

Publication type:

Article

Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients.

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00233-5

By:

Ali, Magdi A.;
Zahra, Omar Shebl;
Morsi, Mohmed I.;
El Safwany, Mohamed M.;
El Feky, Shaymaa Essam

Publication type:

Article

The Christie score for post-treatment response assessment PET/CT in patients with head and neck squamous cell carcinoma: a safe and simple scoring system.

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00230-8

By:

Baguley, N.;
Barker, C.;
Bonington, S.;
Mak, S.;
Chander, A.;
Price, J.;
Datta, A.;
Nadir, R.;
Betts, G.

Publication type:

Article

Brown tumors in primary hyperparathyroidism initially interpreted as bone metastases and multiple gigantocelular tumors: case report.

Published in:

2024

By:

Gladić Nenadić, Vedrana;
Punda, Marija;
Tabain, Anita;
Jukić, Tomislav

Publication type:

Case Study

Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients.

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00227-3

By:

Gadens Zamboni, Camila;
Dundar, Ayca;
Jain, Sanchay;
Kruzer, Marc;
Loeffler, Bradley T.;
Graves, Stephen A.;
Pollard, Janet H.;
Mott, Sarah L.;
Dillon, Joseph S.;
Graham, Michael M.;
Menda, Yusuf;
Shariftabrizi, Ahmad

Publication type:

Article

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine.

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00228-2

By:

Loeff, Cato C.;
van Gemert, Willemijn;
Privé, Bastiaan M.;
van Oort, Inge M.;
Hermsen, Rick;
Somford, Diederik M.;
Nagarajah, James;
Heijmen, Linda;
Janssen, Marcel J. R.

Publication type:

Article

Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00225-5

By:

Glemser, Philip Alexander;
Freitag, Martin;
Kovacs, Balint;
Netzer, Nils;
Dimitrakopoulou-Strauss, Antonia;
Haberkorn, Uwe;
Maier-Hein, Klaus;
Schwab, Constantin;
Duensing, Stefan;
Beuthien-Baumann, Bettina;
Schlemmer, Heinz-Peter;
Bonekamp, David;
Giesel, Frederik;
Sachpekidis, Christos

Publication type:

Article

Mapping the evolution of PET/MR research: a bibliometric analysis of publication trends, leading contributors, and conceptual frameworks (2011–2023).

Published in:

EJNMMI Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1186/s41824-024-00224-6

By:

Li, Jiajin;
Ye, Chuntao;
Li, Shihong;
Lin, Guangwu

Publication type:

Article

Works matching IS 3005074X AND DT 2024 AND VI 8 AND IP 1

Real world experience with [<sup>99m</sup>Tc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry.

Predictive role of [<sup>18</sup>F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients.

The Christie score for post-treatment response assessment PET/CT in patients with head and neck squamous cell carcinoma: a safe and simple scoring system.

Brown tumors in primary hyperparathyroidism initially interpreted as bone metastases and multiple gigantocelular tumors: case report.

Inter- and intra-tumoral heterogeneity on [<sup>68</sup>Ga]Ga-DOTA-TATE/[<sup>68</sup>Ga]Ga-DOTA-TOC PET/CT predicts response to [<sup>177</sup>Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients.

[<sup>18</sup>F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [<sup>18</sup>F]Fluciclovine.

Enhancing the diagnostic capacity of [<sup>18</sup>F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.

Mapping the evolution of PET/MR research: a bibliometric analysis of publication trends, leading contributors, and conceptual frameworks (2011–2023).